Sakar Healthcare reports 42% revenue growth in Q4FY26

Kinjal — Wed, 13 May 2026 05:24:46 +0000

Sakar Healthcare has reported a significant 42% year-on-year growth in revenue for the fourth quarter of the financial year 2026, reaching ₹7,109.70 lakhs. The company’s EBITDA also saw a substantial increase of 67%, amounting to ₹2,623.57 lakhs, with EBITDA margins improving to 37%.

The company’s consolidated financial performance for the entire fiscal year 2026 also reflected strong growth, with revenue from operations totalling ₹25,173.60 lakhs, marking a 42% increase from the previous year. The gross profit for FY26 rose by 35% to ₹12,845.93 lakhs, while the profit after tax surged by 74% to ₹3,048.46 lakhs, highlighting the company’s enhanced profitability.

Sakar Healthcare’s business highlights for the quarter and fiscal year included the completion of over 60 business contracts related to oncology products, with more than 35 ongoing discussions. Out of the 250 dossiers shared globally, 125 have been submitted, and 12 have received marketing authorisations from regulatory authorities.

The company also made significant progress in its technology transfer projects with oncology products for various partners, including Accord-Intas, Torrent-UK & Germany, Emcure, Glenmark, and Zydus. Four projects have received site variation approvals, two each in the UK and the EU.

Sanjay Shah, Managing Director of Sakar Healthcare, commented on the results, stating that the quarter marked a meaningful step forward for the company, with strong growth and improved profitability. He emphasised the strategic importance of the oncology division in the company’s growth strategy, supported by a widening product base and growing export opportunities.

Looking ahead, Sakar Healthcare anticipates that FY27 will be a pivotal year, with continued export momentum and increasing oncology volumes supporting the next phase of growth for the company.

Disclaimer: This article is based on a regulatory filing submitted to the National Stock Exchange of India (NSE).

This article is written by Kinjal and reviewed by Aditya Bhagchandani before publication.

Sanjay Shah | Business Upturn

Sakar Healthcare reports 42% revenue growth in Q4FY26